Results of preclinical studies with the ANGPTL4 antibody, MAR001, support its therapeutic potential and help allay safety concerns about ANGPTL4 inhibition. The results, published in eBioMedicine, show that, in cynomolgus monkeys with hypertriglyceridaemia, a single dose of MAR001 3 mg/kg sc reduced plasma TG by more than 40% from baseline within three days of dosing and led to a peak TG reduction of 58% on day 7 post-dose. MAR001 consistently lowered plasma TG by more than 40% from baseline on days 3 through 21 post-dose. There were also reductions in non-HDL-C, apoB and remnant cholesterol (RC) of 38%, 30%, and 59% respectively.
